home / stock / lumo / lumo quote
Last: | $2.77 |
---|---|
Change Percent: | 0.59% |
Open: | $2.7436 |
Close: | $2.77 |
High: | $2.78 |
Low: | $2.7436 |
Volume: | 688 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.77 | $2.7436 | $2.77 | $2.78 | $2.7436 | 688 | 04-26-2024 |
$2.76 | $2.7133 | $2.76 | $2.81 | $2.7133 | 1,569 | 04-25-2024 |
$2.795 | $2.9 | $2.795 | $2.93 | $2.72 | 46,348 | 04-24-2024 |
$2.8 | $2.73 | $2.8 | $2.85 | $2.7 | 17,078 | 04-23-2024 |
$2.68 | $2.67 | $2.68 | $2.695 | $2.6 | 4,652 | 04-22-2024 |
$2.59 | $2.65 | $2.59 | $2.83 | $2.53 | 12,311 | 04-19-2024 |
$2.62 | $2.45 | $2.62 | $2.76 | $2.41 | 12,387 | 04-18-2024 |
$2.52 | $2.45 | $2.52 | $2.56 | $2.41 | 14,403 | 04-17-2024 |
$2.52 | $2.585 | $2.52 | $2.69 | $2.46 | 18,763 | 04-16-2024 |
$2.45 | $2.42 | $2.45 | $2.57 | $2.41 | 28,476 | 04-15-2024 |
$2.64 | $2.72 | $2.64 | $2.72 | $2.41 | 15,356 | 04-12-2024 |
$2.71 | $2.79 | $2.71 | $2.8999 | $2.69 | 23,100 | 04-11-2024 |
$2.69 | $2.69 | $2.69 | $2.69 | $2.69 | 583 | 04-10-2024 |
$2.69 | $2.685 | $2.69 | $2.7719 | $2.65 | 4,262 | 04-09-2024 |
$2.65 | $2.8 | $2.65 | $2.84 | $2.65 | 9,133 | 04-08-2024 |
$2.74 | $2.81 | $2.74 | $2.8105 | $2.74 | 2,550 | 04-05-2024 |
$2.78 | $2.78 | $2.78 | $2.8356 | $2.6001 | 12,271 | 04-04-2024 |
$2.76 | $2.82 | $2.76 | $2.85 | $2.76 | 6,918 | 04-03-2024 |
$2.84 | $2.79 | $2.84 | $2.84 | $2.75 | 3,462 | 04-02-2024 |
$2.84 | $2.86 | $2.84 | $2.9046 | $2.7976 | 4,523 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lumos Pharma Inc. Company Name:
LUMO Stock Symbol:
NASDAQ Market:
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase ...
Lumos Pharma (NASDAQ: LUMO) , a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (“PGHD”) through phase 2 clinical trials, has received a notice of allowance for a submitted patent. The notice was received from the U.S. P...
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic ca...